As of today (2024-05-06), Epizyme's share price is $1.47. Epizyme's Tangible Book per Share of Jun. 2022 for the quarter that ended in Jun. 2022 was $-0.36. Hence, Epizyme's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for Epizyme's Price-to-Tangible-Book or its related term are showing as below:
During the past 11 years, Epizyme's highest Price to Tangible Book Ratio was 21.72. The lowest was 0.00. And the median was 4.64.
EPZM's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.73 * Ranked among companies with meaningful Price-to-Tangible-Book only.
A closely related ratio is called PB Ratio. As of today, Epizyme's share price is $1.47. Epizyme's Book Value per Sharefor the quarter that ended in Jun. 2022 was $-0.12. Hence, Epizyme's P/B Ratio of today is .
Epizyme Price-to-Tangible-Book Historical Data
The historical data trend for Epizyme's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Epizyme's Price-to-Tangible-Book
For the Biotechnology subindustry, Epizyme's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epizyme's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Epizyme's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Epizyme's Price-to-Tangible-Book falls into.
Epizyme Price-to-Tangible-Book Calculation
Epizyme's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Epizyme Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Epizyme's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EPZM has been successfully added to your 